MX2024013673A - Metodos para tratar la enfermedad de pompe - Google Patents

Metodos para tratar la enfermedad de pompe

Info

Publication number
MX2024013673A
MX2024013673A MX2024013673A MX2024013673A MX2024013673A MX 2024013673 A MX2024013673 A MX 2024013673A MX 2024013673 A MX2024013673 A MX 2024013673A MX 2024013673 A MX2024013673 A MX 2024013673A MX 2024013673 A MX2024013673 A MX 2024013673A
Authority
MX
Mexico
Prior art keywords
methods
pompe disease
treating pompe
treating
population
Prior art date
Application number
MX2024013673A
Other languages
English (en)
Spanish (es)
Inventor
Jay Barth
Sheela Sitaraman Das
Jeff Castelli
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2024013673A publication Critical patent/MX2024013673A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2024013673A 2022-05-05 2024-11-05 Metodos para tratar la enfermedad de pompe MX2024013673A (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202263338601P 2022-05-05 2022-05-05
US202263399498P 2022-08-19 2022-08-19
US202263399491P 2022-08-19 2022-08-19
US202263404475P 2022-09-07 2022-09-07
US202263414897P 2022-10-10 2022-10-10
US202263428970P 2022-11-30 2022-11-30
US202263431920P 2022-12-12 2022-12-12
US202263434791P 2022-12-22 2022-12-22
US202363447222P 2023-02-21 2023-02-21
PCT/US2023/066657 WO2023215865A1 (en) 2022-05-05 2023-05-05 Methods for treating pompe disease

Publications (1)

Publication Number Publication Date
MX2024013673A true MX2024013673A (es) 2024-12-06

Family

ID=86692686

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013673A MX2024013673A (es) 2022-05-05 2024-11-05 Metodos para tratar la enfermedad de pompe

Country Status (13)

Country Link
US (1) US20260041744A1 (enExample)
EP (1) EP4518885A1 (enExample)
JP (1) JP2025515159A (enExample)
KR (1) KR20250007602A (enExample)
CN (1) CN119343147A (enExample)
AU (1) AU2023265155A1 (enExample)
CA (1) CA3252291A1 (enExample)
CL (1) CL2024003377A1 (enExample)
CO (1) CO2024016724A2 (enExample)
IL (1) IL316776A (enExample)
MX (1) MX2024013673A (enExample)
TW (1) TW202400212A (enExample)
WO (1) WO2023215865A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026006625A1 (en) 2024-06-26 2026-01-02 Amicus Therapeutics, Inc. Miglustat formulations comprising nitrosamine for use in the treatment of pompe disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
US11382980B2 (en) 2013-10-08 2022-07-12 Taiyo Kagaku Co., Ltd. Oil/fat composition containing polyunsaturated fatty acid
JP6851964B2 (ja) * 2014-09-30 2021-03-31 アミカス セラピューティックス インコーポレイテッド 炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ
IL299470B2 (en) * 2015-12-30 2026-05-01 Amicus Therapeutics Inc Improved acid alpha-glucosidase for the treatment of Pompe disease
CA3019354A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
KR102618519B1 (ko) * 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
CN119113091A (zh) * 2017-05-15 2024-12-13 阿米库斯治疗学公司 重组人类酸性α-葡萄糖苷酶
WO2020163480A1 (en) 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof
JP2024506346A (ja) * 2021-02-11 2024-02-13 アミカス セラピューティックス インコーポレイテッド 組換えヒト酸性アルファグルコシダーゼ及びその使用

Also Published As

Publication number Publication date
IL316776A (en) 2025-01-01
CN119343147A (zh) 2025-01-21
CA3252291A1 (en) 2023-11-09
AU2023265155A1 (en) 2024-12-12
KR20250007602A (ko) 2025-01-14
WO2023215865A1 (en) 2023-11-09
CL2024003377A1 (es) 2025-03-28
US20260041744A1 (en) 2026-02-12
CO2024016724A2 (es) 2025-04-28
JP2025515159A (ja) 2025-05-13
EP4518885A1 (en) 2025-03-12
TW202400212A (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
JP2023011696A (ja) 核酸産物およびその投与方法
EP2337790B1 (en) Clostridial neurotoxins with altered persistency
BR112013030432A2 (pt) método para preparar um peptídeo conjugado alvo para uma enzima lisossomal recombinante, método para preparar uma molécula para terapia de reposição de enzima, conjugado, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um paciente sofrendo da doença de pompe, doença de fabry, e doença de gaucher, mps i, mps ii, mps vii, tay sachs, sandhoff, alfa-manosidose, e wohlman, sequência de dna e sequência de aminoácidos
TW202247855A (zh) 非蛋白梭菌毒素組成物
BR112023016212A2 (pt) Alfa-glucosidase ácida humana recombinante e usos da mesma
JP7162059B2 (ja) 自律神経障害の治療
MX2025006410A (es) Fexamétodos para tratar la enfermedad de pompe de inicio infantil en pacientes pediátricos
BR112023001121A2 (pt) Cepa c de prevotella histicola como uma terapia oral para doenças inflamatórias
EP4552693A3 (en) Collagen peptide-based medicament compositions and devices and methods of production and use thereof
WO2023070082A3 (en) Rnai agents for inhibiting expression of matrix metalloproteinase 7(mmp7), compositions thereof, and methods of use
JOP20240081A1 (ar) مُعدِّلات الجزيئات الصغيرة لنشاط الجلوكوسيريبروسيد واستخداماتها
WO2023150493A3 (en) Cell therapy for diabetes
CO2024016724A2 (es) Métodos para tratar la enfermedad de pompe
MX2025006409A (es) Métodos para tratar la enfermedad de pompe de inicio tardío en pacientes pediátricos
BRPI0416434A (pt) métodos para aumentar a atividade de uma proteìna de ácido esfingomielinase (asm), para estender a meia-vida e prolongar a atividade de uma proteìna asm purificada, para aumentar a produção de uma proteìna asm recombinante através de uma célula hospedeira, e usos de uma composição de asm tipo alelo-selvagem, purificada e um composto análogo de ceramida ou esfingomielina, e de um composto análogo de ceramida ou de esfingomielina
BR112022014119A2 (pt) Administração oral de peptídeos
BR112022012918A2 (pt) Variantes de enzima de exaustão de metiltioadenosina/adenosina humana melhorada para terapia do câncer
ES2374619T3 (es) Uso de hialuronidasa para la profilaxis y el tratamiento de enfermedades cardiovasculares.
JP6578323B2 (ja) フィラグリン産生促進剤
US20250018016A1 (en) Botulinum neurotoxin composition
WO2024182608A3 (en) Chemogenetics-based therapy for neurological disorders
AR131257A1 (es) Métodos para tratar la enfermedad de pompe de inicio infantil en pacientes pediátricos
BR112022025314A2 (pt) Composições e métodos para tratamento de doença de pompe de início tardio
WO2021216755A9 (en) Compositions and methods for intranasal treatment with double stranded rna
WO2025059390A3 (en) Engineered interferon-beta proteins